Roundtable discussion: How lessons learned from HIV can inform the global response to viral hepatitis

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Lazarus, Jeffrey V ^a   Lundgren, Jens ^a   Casabona, Jordi ^b   Wiessing, Lucas ^c   Matheï, Catharina ^d   Vickerman, Peter ^e,f   Prins, Maria ^g,h   Kretzschmar, Mirjam ^i,j   Kantzanou, Maria ^k   Giraudon, Isabelle ^c   Ferri, Marica ^c   Griffiths, Paul ^c   Harris, Magdalena ^e   Walker, Margaret ^l   Chavdarova, Lilyana ^l   Schatz, Eberhard ^m   Schiffer, Katrin ^m   Kools, John Peter ^m   Farell, Jason ^m   Mendão, Luís ^n,o  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b CEESCAT Center for Epidemiological Studies on HIV/AIDS of Catalonia   (Spain)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l European Liver Patients' Associaton   (Belgium)

^m Correlation European Network Social Inclusion and Health ^*  (Netherlands)

ⁿ Grupo Português de Ativistas sobre Tratamentos de VIH SIDA Pedro Santos   (Portugal)

^o EUROPEAN AIDS TREATMENT GROUP   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

CD4 LYMPHOCYTE COUNT; DISEASE SURVEILLANCE; EPIDEMIC; HARM REDUCTION; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS C; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; INCIDENCE; MIXED INFECTION; NEEDLE SHARING; NOTE; SAFE SEX; STIGMA; VIRUS HEPATITIS; VIRUS LOAD; VIRUS TRANSMISSION; COMPLICATION; EUROPE; HEALTH; HEALTH CARE POLICY; HIV INFECTIONS; SUBSTANCE ABUSE; TRANSMISSION;

EUROPE; GLOBAL HEALTH; HEALTH POLICY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84929513596     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S6-S18     Document Type: Note

References (22)

1. Mocroft A, Lundgren JD, Sabin M, et al: Risk Factors and Outcomes for Late Presentation for HIV-positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013, 10:9.
2. HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. Working Group on Estimation of HIV Prevalence in Europe. AIDS 2011, 25(8):1017-23, doi: 10.1097/QAD.0b013e3283467087.
3. Sullivan A, Raben D, Reekie J, et al: Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES 1 (HIV Indicator Diseases across Europe Study). PlosOne 2013, 8:1.
4. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
5. Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115.
6. World Health Organisation. Hepatitis C-Fact sheet No 164. 2014.
7. Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M, Cowan SA: European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs)-the need to improve quality and comparability. Euro Surveill 2008, 13:pii=18884.
8. Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014, 142:270-286.
9. Bravo MJ, Vallejo F, Barrio G, Brugal MT, Molist G, Pulido J, et al: HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. Int J Drug Policy 2012, 23:415-419.
10. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Boothe R, Abdool R, et al: HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010, 376:268-284.
11. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen K, et al: Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. Plos One. 2014 Jul 28;9(7):e103345. doi: 10.1371/journal. pone.0103345.
12. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J: Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011, 16:pii=20031.
13. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2014. Lisbon, EMCDDA 2014.
14. Wiessing L, Likatavicius G, Klempova D, Hedrich D, Nardone A, Griffiths P: Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health 2009, 99:1049-1052.
15. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L: Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 2010, 105:311-318.
16. Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, et al: Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend 2013, 132:172-181.
17. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al: Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill 2011, 16:pii=20032.
18. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al: Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe? Euro Surveill 2013, 18:pii=20648.
19. Kretzschmar M, Wiessing L: New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users. AIDS 2008, 22:1527-1537.
20. Kretzschmar M, Wiessing L: Coordination of a working group to develop mathematical and statistical models and analyses of protective factors for HIV infection among injecting drug users. 2007. Report. Lisbon, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2007.
21. Grebely J, Dore G: Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Research 2014, 104:62-72.
22. Nguyen V-K, Bajos N, Dubois-Arber, et al: Remedicalising an epidemic: from HIV treatment as prevention to HIV treatment is prevention. AIDS 2011, 25(3):291-3.